Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer

A Phase I Open-label Dose Escalation Study to Assess the Safety and Tolerability of AZD2171 Following Multiple Oral Doses in Subjects With Advanced Prostate Cancer.

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00502164

Acronym

AZD2171IL/0003

Enrollment

Registered

2007-07-17

Start date

2004-03-31

Completion date

Unknown

Last updated

2011-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Prostate Adenocarcinoma

Keywords

Advanced Prostate Cancer

Brief summary

A study to assess safety and tolerability of AZD2171 after multiple doses in patients with advanced prostate cancer.

Interventions

DRUGAZD2171

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Men, 18yrs and older * Histological or cytological confirmation of prostate adenocarcinoma (symptomatic or asymptomatic) * Prior hormonal therapy, and/or no more than 1 prior chemotherapy regimen (including estramustine and/or corticosteroids) for treatment of prostate adenocarcinoma

Exclusion criteria

* Prior radiotherapy to bone metastases within 4 weeks prior to screening * any unresolved chronic toxicity greater than CTCAE grade 2 from previous anticancer therapy * Brain metastases or spinal cord compression, unless treated at least 4 weeks before entry, and stable with steroid treatment for 1 week.

Design outcomes

Primary

Measure	Time frame
To establish the safety and tolerability of AZD2171 in subjects with advanced prostate adenocarcinoma	—

Secondary

Measure	Time frame
Explore the PK profile of AZD2171 at steady-state administration to subjects	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026